Fmr LLC Buys 25,176 Shares of Artivion, Inc. (NYSE:AORT)

FMR LLC increased its stake in Artivion, Inc. (NYSE:AORT - Free Report) by 28.0% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 115,184 shares of the company's stock after purchasing an additional 25,176 shares during the period. FMR LLC owned 0.27% of Artivion worth $3,066,000 as of its most recent SEC filing.

Several other large investors have also recently bought and sold shares of AORT. nVerses Capital LLC bought a new stake in Artivion in the second quarter valued at about $28,000. RiverPark Advisors LLC acquired a new position in shares of Artivion in the 2nd quarter valued at approximately $55,000. RW Investment Management LLC acquired a new position in shares of Artivion in the 2nd quarter valued at approximately $219,000. Intech Investment Management LLC bought a new stake in Artivion during the 2nd quarter worth approximately $253,000. Finally, XTX Topco Ltd acquired a new stake in Artivion during the 2nd quarter worth approximately $331,000. Institutional investors and hedge funds own 86.37% of the company's stock.

Insiders Place Their Bets

In other news, SVP Jean F. Holloway sold 8,070 shares of the company's stock in a transaction dated Wednesday, December 11th. The shares were sold at an average price of $30.12, for a total value of $243,068.40. Following the sale, the senior vice president now directly owns 153,862 shares of the company's stock, valued at approximately $4,634,323.44. This represents a 4.98 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CAO Amy Horton sold 4,329 shares of Artivion stock in a transaction dated Friday, December 6th. The stock was sold at an average price of $29.66, for a total value of $128,398.14. Following the transaction, the chief accounting officer now owns 135,660 shares of the company's stock, valued at $4,023,675.60. The trade was a 3.09 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 32,447 shares of company stock valued at $925,424 in the last 90 days. 8.10% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

A number of equities analysts have issued reports on AORT shares. JMP Securities reiterated a "market outperform" rating and set a $33.00 target price on shares of Artivion in a report on Tuesday, December 10th. Needham & Company LLC reiterated a "buy" rating and set a $34.00 price objective on shares of Artivion in a report on Monday, December 9th. Stifel Nicolaus boosted their target price on Artivion from $28.00 to $30.00 and gave the company a "buy" rating in a research note on Friday, September 13th. Finally, Oppenheimer raised their price target on shares of Artivion from $30.00 to $32.00 and gave the stock an "outperform" rating in a research note on Friday, November 8th. Five investment analysts have rated the stock with a buy rating, According to data from MarketBeat, Artivion currently has an average rating of "Buy" and a consensus target price of $31.80.

Artivion Stock Down 1.9 %

AORT traded down $0.57 on Friday, hitting $28.93. 201,425 shares of the company were exchanged, compared to its average volume of 226,723. The stock's fifty day moving average is $27.70 and its 200-day moving average is $26.24. Artivion, Inc. has a 12 month low of $16.48 and a 12 month high of $30.45. The company has a debt-to-equity ratio of 0.71, a quick ratio of 1.33 and a current ratio of 1.88. The company has a market cap of $1.21 billion, a PE ratio of -1,446.50 and a beta of 1.75.

Artivion Company Profile

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.